Therapeutic Measures in Tardive Dyskinesia;Therapeutische Maßnahmen bei späten extrapyramidalen Hyperkinesen

Fortschritte der Neurologie Psychiatrie

Volumn 51, Issue 6, 1983, Pages 203-226

  Tegeler, J ^a   Woller W ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; DEANOL; DOPA; NEUROLEPTIC AGENT; PHOSPHATIDYLCHOLINE; VALPROIC ACID; 5 HYDROXYTRYPTOPHAN; APOMORPHINE; BENZATROPINE MESILATE; BIPERIDEN; CHLORPROMAZINE; CHOLINE; CHOLINE CITRATE; CLONAZEPAM; CLONIDINE; CLORAZEPATE; CLORAZEPATE DIPOTASSIUM; CLOZAPINE; CYPROHEPTADINE; DIAZEPAM; DIHYDROERGOTOXINE; DIHYDROERGOTOXINE MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; EUNERPAM; HALOPERIDOL; LETHIKON; LEVODOPA; LITHIUM; MANGANESE; MELPERONE; METENKEPHALIN; METHYLDOPA; METIROSINE; METOCLOPRAMIDE; MUSCIMOL; NITAMAN; OXIPEROMIDE; OXYPERTINE; PAPAVERINE; PERPHENAZINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PIRACETAM; POSPERTIN; PRAVIDOL; PROPRANOLOL; PYRIDOXINE; RESERPINE; SULPIRIDE; TETRABENAZINE; THIOPROPAZATE; THIOPROPERAZINE; THIOPROPERAZINE METHANESULFONATE; THIORIDAZINE; TIAPIDEX; TIAPRIDE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; VIGABATRIN;

AGE; ARTICLE; DYSKINESIA; HUMAN; SCHIZOPHRENIA; ADVERSE DRUG REACTION; CENTRAL NERVOUS SYSTEM; DRUG THERAPY; DRUG WITHDRAWAL; INTOXICATION; NERVOUS SYSTEM; NEUROTOXICITY; PSYCHOSIS; REVIEW; TARDIVE DYSKINESIA; THERAPY;

AGE FACTORS; AMANTADINE; ANTIPSYCHOTIC AGENTS; BACLOFEN; BENZODIAZEPINES; BROMOCRIPTINE; DEANOL; DIHYDROXYPHENYLALANINE; DYSKINESIA, DRUG-INDUCED; ENGLISH ABSTRACT; HUMAN; PHOSPHATIDYLCHOLINES; SCHIZOPHRENIA; VALPROIC ACID;

EID: 0020644033     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-2007-1002227     Document Type: Article

References (247)

1. Albanese, H., K. Gaarder: Biofeedback treatment of tardive dyskinesia - Two case reports. Am. J. Psychiatry 134 (1977) 1149-1150
2. Alpert, M., F. Diamond, A. Friedhoff: Tomographic studies in tardive dyskinesia. Psychopharmacology 12 (1976) 5-7
3. Angst, H., D. Bente, P. Bemer, H. Heimann, H. Helmchen, H. Hippius: Das klinische Wirkungsbild von Clozapin (Unter-suchung mit dem AMP-System). Pharmakopsychiat. 4 (1971) 201-211
4. Asnis, CM., M.A. Leopold, R.C. Duvoisin: A survey of tardive dyskinesia in psychiatric outpatients. Am. J. Psychiatry 134 (1977) 1367-1370
5. Asnis, CM., M.A. Leopold: A single-blind study of ECT in patients with tardive dyskinesia. Am. J. Psychiatry 135 (1978) 1235-1237
6. Bacher, N.M., H.A. Lewis: Low-dose propranolol in tardive dyskinesia. Am. J. Psychiatry 137 (1980) 495-497
7. Barbeau, A.: Lecithin in neurologic disorders (ltr. to ed). N. Engl. J. Med. 299 (1978) 200
8. Barnes, T., T. Kidger, P. Taylor: On the use of dopamine agonists in tardive dyskinesia. Am. J. Psychiatry 135 (1978) 132-133
9. Bartels, M., C. Mezger, C. Schmalzing, P.W. Schdnle: Langzeitbehandlung der tardiven Dyskinesie mit Lecithin. Vortrag 12. Nürnberger AGNP Symposion (1981)
10. Bateman, D.N., D.K. Dutta, H.A. McClelland, M.D. Rawlins: Metoclopramide and haloperidol in tardive dyskinesia. Brit. J. Psychiatry 135 (1979) 505-508
11. Bedard, P., J. Parkes, C. Marsden: Effect of new dopamine- blocking agent (Oxiperomide) on drug induced dyskinesias in Parkinson's disease and spontaneous dyskinesias. Brit. Med. J. (1978) 954-956
12. Beitman, B.D.: Tardive dyskinesia reinduced by lithium carbonate. Am. J. Psychiatry 135 (1978) 1229-1230
13. Birkmayer, W., E. Neumayer: Die Behandlung der Dopa-Psychosen mit L-Tryptophan. Nervenarzt 43 (1972) 76-78
14. Bjerkenstedt, L., C. Härnryd, C Sedvall: The effect of sulpiride on monoaminergic mechanisms in psychotic women. Psychopharmacology 64 (1979) 135-139
15. Bockenheimer, S., C Lucius: Zur Therapie mit Dimethylaminoethanol (Deanol) bei neuroleptikainduzierten extrapyra-midalen Hyperkinesen. Arch. Psychiat. Nervenkr. 222 (1976) 69-75
16. Bourgeois, M., A. Hibert: Les dyskinesies tardives des neuroleptiques. Bord. Med. 3 (1970) 345-352
17. Brandrup, E.: Tetrabenazine treatment in persisting dyskinesia caused by psychopharmaca. Am. J. Psychiatry 118 (1961) 551-552
18. Bucci, L.: The dyskinesias - a new therapeutic approach. Dis. Nerv. Syst. 32 (1971) 324-327
19. Caine, E.D., R.J. Polinsky, R. Kartiziner, MM. Ebert: The trial use of clozapine for abnormal involuntary movement disorders. Am. J. Psyohiatry 136 (1979) 317-320
20. Caroll, B.J., C.C. Curtis, E. Kokmen: Paradoxical response to dopamine agonists in tardive dyskinesia. Am. J. Psychiatry 134 (1977) 785-789
21. Carruthers, S.C.: Persistent tardive dyskinesia. Brit. Med. J. 3 (1971) 572
22. Casey, D.E.: Deanol in the management of involuntary movement disorders: a review. Dis. Nerv. Syst. 38 (1977) 7-15
23. Casey, D.E., D. Denney: Dimethylyaminoethanol in tardive dyskinesia. N. Engl. J. Med. 291 (1974) 797
24. Casey, D.E., D. Denney: Deanol in the treatment of tardive dyskinesia. Am. J. Psychiat. 132 (1975) 864-867
25. Casey, D.E., D. Denney: Pharmacological characterization of tardive dyskinesia. Psychopharmacology 54 (1977) 1-8
26. Casey, D.E., J. Gerlach, H. Simmelgaard: Sulpiride in tardive dyskinesia. Psychopharmacology 68 (1979) 73-77
27. Casey, D.E., J. Gerlach: Oxiperomide in tardive dyskinesia. J. Neurol. Neurosure. Psychiatry 42 (1979) 318-321
28. Casey, D.E., J.P. Hammerstad: Sodium valproate in tardive dyskinesia. J. Clin. Psychiatry 40 (1979) 483-485
29. Casey, D.E., J. Gerlach, G. Magelund, T. Rosted Christensen: Gamma-acetylenic GABA (GAG) in tardive dyskinesia. Arch. Gen. Psychiatry 37 (1980) 1376-1379
30. Casey, D.E., S. Korsgaard, J. Gerlach: Des-tyr-gamma-endorphin in tardive dyskinesia. III. World Congress of Biological Psychiatry Stockholm (1981)
31. Chase, T.N., C.A. Tamminga: GABA system participation in motor, cognitive and endocrine function in man. In: P. Krogs-gaard-Larsen, J. Scheel-Krüger, H. Kofod (eds.): GABA-neuro-transmitters. Pharmacochemical, biochemical and pharmacological aspects. Academic Press. New York (1979) 283-295
32. Chien, CP., J.O. Cole: Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study. Am. J. Psychiatry 130 (1973) 13-18
33. Chien, CP., K. Jung, A. Ross-Townsend: Efficacies of agents related to GABA, dopamine and acetylcholine in the treatment of tardive dyskinesia. Psychopharmacol. Bull. 14 (1978) 20-22
34. n CINP Congress. Supplement to Progress in Neuropsychopharma-cology. Pergamon Press (1980)
35. Chouinard, C, C. de Montigny, L. Annable: Tardive dyskinesia and antiparkinsonian medication. Am. J. Psychiatry 136 (1979) 228-229
36. th CINP Congress. Supplement to Progress in Neuropsychopharmacology. Pergamon Press (1980)
37. Christensen. A.V., B. Fjalland, I. Moller Nielsen: On the supersensitivity of dopamine receptors, induced by neuroleptics. Psychopharmacology 48 (1976) 1-6
38. Claus, D., J.C. Aschoff: Behandlung extrapyramidal Bewe-gungsstorungen mit Tiaprid. Arch. Psychiat. Nervenkr. 227 (1979) 151-158
39. Claveria, I.E., P.F. Teychenne, D.B. Calne, L. Haskayne, A. Petrie, C.A. Pallis, I.C. Lodge-Patsch: Tardive dyskinesia treated with pimozide. J. Neurol. Sci. 24 (1975) 393-401
40. Cole, J.O., G. Gardos, R. Granacher: Drug evaluations in tardive dyskinesia; papaverine and deanol. Presented at the 129th annual meeting of the American Psychiatric Association. Miami Beach (1976)
41. Cools, A.R., J.M. van Rossum: Excitation-mediating and inhibition-mediating dopamine receptors: A new concept towards a better understanding of the electrophysiological, biochemical, pharmacological functional and clinical data. Psychopharmacologia 45 (1976) 243-245
42. Costall, B., R.J. Nay lor: Experimental studies of dopamine function in movement disorders. In: N.J. Legg (ed.): Neurotransmitter systems and their clinical disorders. Academic Press, London (1978) 129-142
43. Costall, B., R.J. Naylor: Démonstration neuropharmacologique de l'effet antidyskinètique du tiapride. Sem. Hop. 53 (1977) 72-76
44. Crane, G.E.: Persistence of neurological symptoms due to neuroleptic drugs. Am. J. Psychiatry 127 (1971) 1407-1410
45. Crane, G.E.: Persistent dyskinesia. Brit. J. Psychiatry 122 (1973) 395-405
46. Crane, G.E.: Deanol for tardive dyskinesia. N. Engl. J. Med. (1975) 292-296
47. Crane, G.E.: The prevention of tardive dyskinesia. Am. J. Psychiatry 134 (1977) 756-758
48. Crane, G.E., G. Paulson: Tardive dyskinesia in patients treated with major neuroleptics. Am. J. Psychiatry 124 (1968) 40-48
49. Crane, G.E., IS. Turek, A.A. Kurland: Failure of pyridoxine to reduce drug-induced dyskinesias. J. Neurol. Neurosurg. Psychiatry 33 (1970) 511-512
50. Crane, G.E., G. Paulson: More about the use of amantadine in tardive dyskinesia. N. Engl. J. Med. 285 (1971) 1150
51. Crawford, R., A. Forrest: Controlled trial of depot-fluphenazine in out-patient schizophrenics. Brit. J. Psychiatry 124 (1974) 385-391
52. Crews, E.L., A.E. Carpenter: Lithium-induced aggravation of tardive dyskinesia. Am. J. Psychiatry 134 (1977) 933
53. Curran, J.P.: Tardive dyskinesia: side effect or not? Am. J. Psychiatry 130 (1973) 406-410
54. Curran, J.P.: Management of tardive dyskinesia with thiopropazate. Am. J. Psychiatry 130 (1973) 925-927
55. Curran, D.J., S. Nagaswami, K.J. Mohan: Treatment of phenothiazine-induced bulbar persistent dyskinesia with deanol acetamidobenzoate. Dis. Nerv. Syst. 36 (1975) 71-73
56. Dalen, P.: Lithium therapy in Huntington's chorea and tardive dyskinesia. Lancet 1 (1973) 107-108
57. Davis, J.M.: Overview: Maintenance therapy in psychiatry: I. Schizophrenia. Am. J. Psychiatry 132 (1975) 1237-1245
58. Davis, K.L., P.A. Berger, L.E. Hollister: Choline for tardive dyskinesia. N. Engl. J. Med. 293 (1975) 152
59. Davis, K.L., P.A. Berger: Pharmacological investigations of the cholinergic imbalance hypotheses of movement disorders and psychosis. Biological Psychiatry 13 (1978) 23-49
60. Decker, B.L., J.M. Davis, D.S. Janowsky, M.K. El Yousef, H.J. Sekerke: Amantadine hydrochloride treatment of tardive dyskinesia. N. Engl. J. Med. 285 (1971) 860
61. Degkwitz, R.: Extrapyramidal motor disorders following longterm treatment with neuroleptic durgs. In: G.E. Crane, R.J. Gardner (eds.): Psychotropic drugs and dysfunction of the basal ganglia. Publication 1938 US Public Health Service. Washington (1969)
62. Docherty, J.P.: Prophylactic efficacy of long acting parenteral vs. short acting oral phenothiazines in schizophrenic. In: Ayd, F.J. (ed.): Depot-fluphenazines: Twelve years of experience. Ayd Medical Communications. Baltimore (1978) 13-22
63. Doepp, S., C. Buddeberg: Extrapyramidal Symptome unter Clozapin. Nervenarzt 46 (1975) 589-590
64. Doller-Wojcek, J., A.J. Gelenberg, R.A. La Brie: Outcome of tardive dyskinesia: unpublished observations at the Massachusetts General Hospital, Boston (1980), aus: Task Force Report. Am. J. Psychiatry 137 (1980) 1163-1172
65. Druckman, R., D. Seelinger, B. Thulin: Chronic involuntary movements induced by phenothiazines. J. Nerv. Ment. Dis. 135 (1962) 69-76
66. Duvoisin, R.: Reserpine for tardive dyskinesia. N. Engl. J. Med. 286 (1972) 611
67. Dynes, J.B.: Oral dyskinesia - Occurrence and treatment. Dis. Nerv. Syst. 31 (1970) 854-859
68. Eckmann, F: Zur Problematik von Dauerschaden nach neuro-leptischer Langzeitbehandlung. Ther. Ggw. 107 (1968) 316-323
69. Edwards, H.: The significance of brain damage in persistent oral dyskinesia. Brit. J. Psychiat. 116 (1970) 271-275
70. Ehrensing, R.H., A.J. Kastin, P.F. Larsons, G.A. Bishop: Melanocyte-stimulating hormone release-inhibiting factor-1 and tardive dyskinesia. Dis. Nerv. Syst. 38 (1977) 303-306
71. Emrich, H.M., M. Zaudig, W. Kissling, G. Dirlich, D. v. Zerssen, A. Herz: Des-tyrosyl-6-endorphin in schizophrenia: a double-blind trial in 13 patients. Pharmakopsychiat. 13 (1980) 290-298
72. Escobar, J., K.F. Kemp: Dimethylaminoethanol for tardive dyskinesia. N. Engl. J. Med. 292 (1975) 317-318
73. Ezrin-Waters, C., P. Seeman: L-Dopa reversal of hyperdopaminergic behaviour. Life Sci. 22 (1978) 1027-1032
74. Fann, W.E., J.M. Davis, I.C. Wilson: Methylphenidate in tardive dyskinesia. Am. J. Psychiatry 130 (1973) 922-924
75. Fann, W.E., CR. Lake, C.J. Gerber, G.M. McKenzie: Cholinergic suppression of tardive dyskinesia. Psychopharmacologia 37 (1974) 101-107
76. Fann, W.E., J.L. Sullivan III, R.D. Miller, G.M. McKenzie: Deanol in tardive dyskinesia - A preliminary report. Psychopharmacologia 42 (1975) 135-137
77. Fleischhauer, J: Sind Anticholinergika als Dauerbehandlung beim neuroleptisch bedingten Parkinson-Syndrom notwendig? Arzneim.-Forsch. (Drug. Res.) 26 (1976) 1183-1184
78. Fleischhauer, J: Influence of piracetam on tardive dyskinesia. 12th C1NP Congress. Supplement to Progress in Neuropsychopharmacology. Pergamon Press (1980)
79. Fog, R., H. Pakkenberg: Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes. Acta. Neurol. Scand. 46 (1970) 249-251
80. Freeman, H.L., S.D. Soni: Treatment of tardive dyskinesia with oxypertine. 12th C1NP Congress. Supplement to Progress in Neuropsychopharmaeology. Pergamon Press (1980)
81. Friedhoff, A.J., H. Rosengarten, K. Bonnet: Receptor-cell sensivity modification (RSM) as a model for pathogenesis and treatment of tardive dyskinesia. Psychopharmacol. Bull. 14 (1978) 77-79
82. Frangos, E., E. Athanasenas: Lioresal in the treatment of neuroleptic induced tardive dyskinesia. 12th CINP Congress Supplement to Progress in Neuropsychopharmaeology. Pergamon Press (1980)
83. Frangos, E., H. Christodoulides: Clinical observations on the treatment of tardive dyskinesia with haloperidol. Acta Psychiat. Belg. 75 (1975) 19-32
84. Gardos, G., JO. Cole, C. Sniffin: An elevation of papaverine in tardive dyskinesia. J. Clin. Pharmacology 16 (1976) 304-310
85. Gardos, G., JO. Cole: Pilot study of cyproheptadine (Periactin) in tardive dyskinesia. Psychopharmacol. Bull. 14 (1978) 18-20
86. Gardos, G., J.O. Cole: Overview: Public health issues in tardive dyskinesia. Am. J. Psychiatry 137 (1980) 776-781
87. Gelenberg, A.J., J.C. Doller-Wojcik, J.H. Growdon: Choline and lecithin in the treatment of tardive dyskinesia: preliminary results from a pilot study. Am. J. Psychiatry 136 (1979) 772-776
88. Gerlach, J.: Antipsychotic treatment with neuroleptics in very high doses. Ugeskr. Laeg. 139 (1977) 959-961
89. Gerlach, J: Relationship between tardive dyskinesia, L-Dopa induced hyperkinesia and parkinsonism. Psychopharmacology 51 (1977) 259-263
90. Gerlach, J.: Tardive dyskinesia. Dan. Med. Bull 26 (1979) 209-245
91. Gerlach, J., N. Reisby, A. Randrup: Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia. Psychophaimacologia 34 (1974) 21-35
92. Gerlach, J., K. Thorsen, R. Fog: Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia 40 (1975) 341-350
93. Gerlach, J., K. Thorsen, I. Munkvad: Effect of lithium on neuroleptic-induced tardive dyskinesia compared with placebo in a double-blind cross-over trial. Pharmakopsychiat. 8 (1975) 51-56
94. Gerlach, J., K. Thorsen: The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. Int. Pharmacopsychiat. 11 (1976) 1-7
95. Gerlach, J., T. Rye, P. Kristjansen: Effect of baclofen on tardive dyskinesia. Psychopharmacology 56 (1978) 145-151
96. Gerlach, J., H. Simmelsgaard: Tardive dyskinesia during and following treatment with haloperidol, haloperidol and biperiden, thioridazine and clozapine. Psychopharmacology 59 (1978) 105-112
97. Gibson, A.C.: Tardive dyskinesia and pimozide. Proceedings of the Royal Society of Medicine 20 (1977) 34-37
98. Gibson, A.C.: Depot injections and tardive dyskinesia. Brit. J. Psychiatry 132 (1978) 361-365
99. Gilbert, M.M.: Haloperidol in severe facial dyskinesia, (a report). Dis. Nerv. Syst. 30 (1969) 481-482
100. Godwin-Austen, R.B., T. Clark: Persistent phenothiazine dyskinesia treated with tetrabenazine. Brit. Med. J. 4 (1971) 25-26
101. Goldberg, A.M., E.R. Silbergeld: Neurological aspects of lead- induced hyperactivity. Trans. Am. Soc. Neurochem. 5 (1974) 185
102. Goldman, D.: Treatment of phenothiazine-induced dyskinesia. Psychopharmacology 47 (1976) 271-272
103. Gomez, E.: Clinical observations in the treatment of tardive dyskinesia with dihydrogenated ergot alkaloids (hydergine), preliminary findings. Psychiatric J. Univ. Ottawa 2 (1977) 67-71
104. Gottfries, C.G.: Flupenthixoldecanoat - Pharmakokinetik und klinische Anwendung. In: K. Heinrich, J. Tegeler (eds.): Die Praxis der Depot-Neurolepsie. Tropon. Das ärztliche Gespräch Bd. 25, Köln (1978)
105. Granacher, R., R. Baldessarini, J. Cole: Deanol for tardive dyskinesia. N. Engl. J. Med. 292 (1975) 926-927
106. Greenblatt, D.L., J.R. Dominick, A. Di Mascio: Extrapyramidal side effects of psychotropic drugs. Conn. Med. 33 (1969) 197-201
107. Growdon, J.H., M.J. Hirsch, R.J. Wurtman, W. Wiener: Oral choline administration to patients with tardive dyskinesia. N. Engl. J. Med. 297 (1977) 524-527
108. Gunne, L.M., S. Bárány: A monitoring test for the liability of neuroleptic drugs to induce tardive dyskinesia. Psychopharmacology 63 (1979) 195-198
109. Haefely, W.E.: Central actions of benzodiazepines: general introduction. Brit. J. Psychiat. 133 (1978) 231-239
110. Hassler, I., I.J. Bak, J.S. Kim: Unterschiedliche Entleerung der Speicherorte für Noradrenalin, Dopamin und Serotonin als Wirkungsprinzip des Oxypertins. Nervenarzt 41 (1970) 105-118
111. Haubrich, D.R., P.F.L. Wang, D.E. Clody, P.W. Wedeking: Increase in rat brain acetylcholine induced by choline or deanol. Life Sci. 17 (1975) 975-980
112. Helmchen, H: Forschungsaufgaben bei psychiatrischer Lang-zeitmedikation. Nervenarzt 49 (1978) 534-538
113. Hershon, H.I., P.F. Kennedy, R.J. McGuire: Persistence of extrapyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Brit. J. Psychiatry 120 (1972) 24-28
114. Hirsch, S.R., R. Gaind, P.D. Rohde, B.C. Stevens, J.K. Wing: Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Brit. Med. J. 17 (1973) 633-637
115. Hippius, H, G. Logemann: Zur Wirkung von Dioxyphenylalanin (L-Dopa) auf extrapyramidal motorische Hyperkinesen nach langfristiger neuroleptischer Therapie. Arzneim.-Forsch. (Drug Res.) 20 (1970) 894-896
116. Hogarty, G.E., S.C. Goldberg, N.R. Schooler, R.F. Ulrich: Drug and sociotherapy in the aftercare of schizophrenic patients: Two year relapse rates. Arch. Gen. Psychiatry 31 (1974) 603-608
117. Hunter, R., C.J. Earl, S. Thornicroft: An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc. R. Soc. Med. 57 (1964) 24-28
118. Hyttel, J.: Dopamine receptor binding and adenylate cyclase activity in mouse striatal tissue in the supersensitivity phase after neuroleptic treatment. Psychopharmacology 59 (1978) 211-219
119. Itil, T.M., C. Unverdi, D. Mehta: Chlorazepate dipotassium in tardive dyskinesia. Am. J. Psychiatry 131 (1974) 1291
120. Iversen, L.L.: More than one type of dopamine receptor in brain? Trends in Neurosci. (1978) 5-6
121. Jackson, I. V., E.A. Nuttall, J. Perez-Cruet: Treatment of tardive dyskinesia with lecithin. Am. J. Psychiatry 136 (1979) 1458-1460
122. Janowsky, D.S., M.K. El-Yousef, J.M. Davis, H.J. Sekerke, D.R. Morris, B. Decker: Effects of amantadine on tardive dyskinesia and pseudoparkinsonism. N. Engl. J. Med. 286 (1972) 785
123. Jenner, P., A. Clow, C. Reavill, A. Theodorou, D.D. Marsden: A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs. Life Sci. 23 (1978) 545-550
124. Jeste, D. V., R.J. Wyatt: In search of treatment for tardive dyskinesia: review of the literature. Schizophrenia Bull. 5 (1979) 251-293
125. Jeste, D.V., S.G. Potkin, S. Sindha, S. Feder, R.J. Wyatt: Tardive dyskinesia - reversible and persistent. Arch. Gen. Psychiatry 36 (1979) 585-590
126. Jφrgenson, A., R. Fog, B. Veilis: Synthetic enkaphalin analogue in treatment of schizophrenia. Lancet 935 (1979)
127. Jung, M.J., B. Lippert, B.W. Metcalf: The effect of 4-aminohex- 5-ynoic acid (δ-acetylenic GABA, δ-ethynyl GABA), a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vivo. J. Neurochem. 28 (1977) 717
128. Jus, K., J. Gautier, A. Villeneuve, P. Pires, R. Pineau, R. Villeneuve: Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome. Int. J. Clin. Pharmacol. 9 (1974) 138-145
129. Jus, A., A. Villeneuve, J. Gautier, K. Jus, C. Villeneuve, P. Pires, R. Villeneuve: Deanol, lithium and placebo in the treatment of tardive dyskinesia. Neuropsychobiology 4 (1978) 140-149
130. Jus, A., K. Jus, P. Fontaine: Long term treatment of tardive dyskinesia. J. Clin. Psychiatry 40 (1979) 72-77
131. Kabes, J., J. Sikora, J. Pisvejc, V. Skoudia: Piracetam action in neuroleptic induced extrapyramidal side-effects. 12th CINP Congress. Supplement to Progress in Neuropsychopharma-cology. Pergamon Press (1980)
132. Kataria, M., M. Traub, CD. Marsden: Extrapyramidal side effects of metaclopramide. Lancet (1978) 1254-1255
133. Kazamatsuri, H.: Treatment of tardive dyskinesia with oxypertine - preliminary clinical experience and a brief review of the literature. Compreh. Psychiatry 21 (1980) 352-357
134. Kazamatsuri, H., C. Chien, J.O. Cole: Therapeutic approaches to tardive dyskinesia. Arch. Gen. Psychiatry 27 (1972) 491-499
135. Kazamatsuri, H., C. Chien, J.O. Cole: Treatment of tardive dyskinesia: I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch. Gen. Psychiatry 27 (1972) 95-99
136. Kazamatsuri, H, C. Chien, J.O. Cole: Treatment of tardive dyskinesia: II. Short-term efficiacy of dopamine-blocking agents haloperidol and thiopropazate. Arch. Gen. Psychiatry 27 (1972) 100-103
137. Kazamatsuri, H, C. Chien, J.O. Cole: Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am. J. Psychiatry 130 (1973) 479-483
138. Kebabian, J.W., D.B. Calne: Multiple receptors for dopamine. Nature 277 (1978) 93-106
139. Kennedy, P.F.: Chorea and phenothiazines. Brit. J. Psychiat. 115 (1969) 103-104
140. Kirkegaard, G., A. Kirkegaard: Nebenwirkungen von Methyl-perone bei Dauerbehandlung bis zu 8 Jahren. Arzneim. Forsch. (Drug. Res.) 24 (1974) 1115-1117
141. Klawans, H.L., R.R. McKedall: Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia. J. Neurol. Sci. 14 (1971) 189-192
142. Klawans, H.L., R. Rubovits: Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J. Neurol. Neurosurg. Psychiat. 27 (1974) 941-947
143. Klawans, H.L., W.J. Weiner, P.A. Nausieda: The effect of lithium on an animal model of tardive dyskinesia. Prog. Neuro-Psycho- pharmac. 1 (1977) 53-60
144. Klawans, H.L., C.G. Goetz, S. Perlik: Tardive dyskinesia: review and update. Am. J. Psychiatry 137 (1980) 900-908
145. Klett, C.I., E. Caffey, P. Point: Evaluating the long term need for antiparkinson drugs by chronic schizophrenics. Arch. Gen. Psychiatry 26 (1972) 374-379
146. Kline, N.S.: On the rarity of,.irreversible" oral dyskinesia following phenothiazines. Am. J. Psychiatry 124 (1968) 48-54
147. Kline, N.S., B.T. Mason, L. Winick: Biperiden (Akineton) effective prophylactic and therapeutic antiparkinsonian agent. Curr. Ther. Res. 16 (1974) 838-843
148. Kobayashi, R.M.: Drug therapy of tardive dyskinesia. N. Engl. J. Med. 296 (1977) 257-260
149. Korsgaard, S.: Baclofen (Lioresal) in the treatment of neuroleptic-induced tardive dyskinesia. Acta Psychiat. Scand. 54 (1970) 17-24
150. Korsgaard, S., D.E. Casey, J. Gerlach: Neuropeptides and GABA influences in tardive dyskinesia. III. World Congress of Biological Psychiatry Stockholm (1981)
151. Kumar, B.B.: Treatment of tardive dyskinesia with deanol. Am. J. Psychiatry 133 (1976) 978
152. Kunin, R.A.: Manganese in dyskinesias. Am. J. Psychiatry 133 (1976) 105
153. Kurland, A., I.S. Turek: Persistent dyskinesia in chronically hospitalized mental patients. In: G.E. Crane, R. Gardner Jr. (eds.): Psychotropic drugs and dysfunction of the basal ganglia. Public Health Service Publication Nr. 1938. Washington D.C. (1968) 4-9
154. Lai, S.: Comparison of thiopropazate and trifluoperazine on oral dyskinesia: a double-blind study. Curr. Therap. Res. 16 (1974) 990-997
155. Laterre, E.C., E. Fortemps: Deanol in spontaneous and induced dyskinesias. Lancet 1 (1975) 1301
156. Lauciello, F., M. Appelbaum: Prosthodontic implications of tardive dyskinesia. New York State Dental Journal 43 (1977) 214-217
157. Lavy, S., E. Melamed, S. Penchas: Tardive dyskinesia associated with metoclopramide. Brit. Med. J. (1978) 77-78
158. Lees, A., C. Lander, G. Stern: Tiapride in Levodopa-induced involuntary movements. J. Neurol. Neurochir. Psychiat. 4 (1979) 380-383
159. Leff, J.P., J.K. Wing: Trial of maintenance therapy in schizophrenia. Brit. Med. J. III (1971) 599-604
160. Lehmann, E., H. Quadbeck, J. Tegeler, M. Fararuni, K. Heinrich: Wirkungsdifferenzen bei Hoch- und Standarddosierung von Flu-phenazin-Decanoat in Abhängigkeit von Patienten-Merkmalen. Pharmakopsychiat. 13 (1980) 117-129
161. Levine, J., N.R. Schooler, J. Severe, J. Escobar, A. Gelenberg, M. Mandel, R. Sovner, R. Steinbook: Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continous medication: a controlled study. Adv. Biochem. Psychopharmacol. 22 (1980)
162. Lhermitte, F., J.L. Signoret, Y. Agid: Etude des eTfets d'une moldcule originale, le tiapride dans le traitement des mouve-ments anormaux d'origine extrapyramidal. Sem. Hop. 53 (1977) 9-15
163. Linnoila, M., M. Viukari, O. Hietala: Effect of sodium valproate on tardive dyskinesia. Brit. J. Psychiat. 129 (1976) 114-119
164. Lipsius, L.H.: Barbiturates and tardive dyskinesia. Am. J. Psychiatry 134 (1977) 1162-1163
165. Ljungberg, T., U. Ungerstedt: Evidence that the different properties of haloperidol and clozapine are not explained by differences in anticholinergic potency. In: T. Ljungberg: Dopaminergic J. Tegeler, W. Woller mechanism investigated with a new method of measuring specific behavioral patterns. Karolinska Institute Stockholm (1978)
166. London, E.D., L.W. Harris, W.C. Hey I, J.T. Coyle: Effect of 2-dimethylaminocthanol in kainate lesioned rat striatum: anomaly in the radioenzymatic assay of acetylcholine. Commun. Psychopharmacol. 2 (1978) 357-364
167. Mackay,- A.V.P., G.P. Sheppard: Pharmacothcrapeutic trials in tardive dyskinesia. Brit. J. Psychiat. 135 (1979) 489-499
168. Mackay, A.V.P., G. Sheppard, B.K. Saha, B. Motley, CD. Marsden: Failure of lithium treatment in established tardive dyskinesia, (submitted for publication.) (1979)
169. Mallya, A., C. Jose, R. Williams, D. Cho, D. Mehta, J. Volavka: Antiparkinsonics, neuroleptics and tardive dyskinesia. Biolog. Psychiatry 14 (1979) 645-649
170. McCullum, W.A.G.: Tetrabcnazine for extrapyramidal motor disorders. Brit. Med. J. 1 (1970) 760
171. Mehta, D., S. Mehta, P. Mathew: Failure of deanol in treating tardive dyskinesia. Am. J. Psychiatry 133 (1976) 1467
172. Mena, I., J. Court, G. Cotzias: Levodopa, involuntary movements and fusaric acid. J.A.M.A. 218 (1971) 1829-1830
173. Merren, M.D.: Amantadine in tardive dyskinesia. N. Engl. J. Med. 286 (1972) 268
174. Mielke, D.H., D.M. Gallant, C. Kessler: An evaluation of a unique new antipsychotic agent, sulpiride: Effects on serum prolactin and growth hormone levels. Am. J. Psychiatry 134 (1977) 1371-1375
175. Miller, E.: Deanol: a solution for tardive dyskinesia? N. Engl. J. Med. 291 (1974) 796-797
176. De Montigny, C., G. Chouinard, L. Annable: Ineffcctiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology 65 (1979) 219-223
177. Moore, D.C., M.B. Bowers: Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes. Am. J. Psychiatry 137 (1980) 1202-1205
178. Nair, N.P.V., S. Lai: Differential effects of GABAergic drugs on nigro-striatal and hypothalamic-pituitary dopaminergic systems. Brain. Res. Bull. 4 (1979) 691
179. Nashold, B.S.: The effects of central tegmental lesions on tardive dyskinesia. In: G.E. Crane, R. Gardner (eds.): Psychotropic drugs and dysfunctions of the basal ganglia. (Public Health Service Publication 1938). Washington D.C: Superintendent of Documents, U.S. Government Printing Office (1969) 111-119
180. Nedopil, N., E. Rüther: Effects of the synthetic analogue of methionine enkaphalin FK 33-824 on psychotic symptoms. Pharmakopsychiat. 12 (1979) 277-280
181. Nesse, R., B.J. Caroll: Cholinergic side effects associated with deanol. Lancet 2 (1976) 50-51
182. Norris, J.P., R.E. Sams: More on the use of manganese in dyskinesia. Am. J. Psychiatry 134 (1977) 1448
183. O'Flanagan, P.M.: Clonazepam in the treatment of drug-induced dyskinesia. Brit. Med. J. 1 (1975) 269-270
184. Pakkenberg, H., R. Fog: Spontaneous oral dyskinesia': results of tetrabenazine, pimozide, or both. Arch. Neurol. 31 (1974) 352-353
185. Paulson, G.W.: An evaluation of the permanence of the tardive dyskinesias. Dis. Nerv. Syst. 29 (1968) 692-694
186. Penovich, P., J.P. Morgan, B. Kerzner, F. Karch, D. Goldblatt: Double-blind evaluation of deanol in tardive dyskinesia. J. Amer. Med. Ass. 239 (1978) 1997-1998
187. Peters, H.A., R.F. Daly, S. Sato: Reserpine for tardive dyskinesia. N. Engl. J. Med. 286 (1972) 106
188. Pietzcker, A.: Langzeitmedikation bei schizophrenen Krankcn. Nervenarzt 49 (1978) 518-533
189. Price, T.R.P., R. Levin: The effects of electroconvulsive therapy on tardive dyskinesia. Am. J. Psychiatry 135 (1978) 991-993
190. Price, P., J. Parices, C. Marsden: Sodium valproate in the treatment of levodopa-induced dyskinesia. J. Neurol. Neurochir. Psychiat. 41 (1978) 702-706
191. Prange, A., J.C. Wilson, C.E. Morris, CD. Hall: Preliminary experience with tryptophan and lithium in the treatment of tardive dyskinesia. Psychopharmacol. Bull. 9 (1973) 36-37
192. Quitkin, F., A. Rifkin, L. Gochfeld, D.F. Klein: Tardive dyskinesia: are first signs reversible? Am. J. Psychiatry 134 (1977) 84-87
193. Reda, F.A., J.I. Escobar, J.M. Scanlon: Lithium carbonate in the treatment of tardive dyskinesia. Am. J. Psychiatry 132 (1975) 560-562
194. Reda, F.A., J.M. Scanlon, K. Kent, J.J. Escobar: Treatment of tardive dyskinesia with lithium carbonate. N. Engl. J. Med. 291 (1979) 850
195. Rifkin, A., F. Quitkin, J. Kane: Are prophylactic antiparkinson drugs necessary? A controlled study of procyclidine withdrawal. Arch. Gen. Psychiatry 35 (1978) 483-489
196. Ringwald, E.: Behandlung von neuroleptischen Späthyperkinesen mit Antiparkinsonika (Ergebnisse einer Vergleichsprüfung mit Bromocriptin, Levodopa und Trihexyphendil). Pharmakopsychiat. 11 (1978) 294-298
197. Rosin, A.J., A.M. Exton-Smith: Persistent oral dyskinesia in treatment with phenothiazine derivatives. Lancet 1 (1965) 651
198. Roxburch, P.A.: Treatment of phenothiazine-induced oral dyskinesia. Brit. J. Psychiat. 116 (1970) 277-280
199. Sato, S., R. Daly, H. Peters: Reserpine therapy of phenothiazine induced dyskinesia. Dis. Nerv. Syst. 32 (1971) 680-685
200. Sayers, A., H. Bürki, W. Ruch, H. Asper: Neuroleptic-induced hypersensivity of striatal dopamine receptors in the rat as a model of tardive dyskinesia. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia 41 (1975) 97-104
201. Sayers, A., H. Bürki, W. Ruch, H. Asper: Anticholinergic properties of antipsychotic drugs and their relation to extrapyramidal side-effects. Psychopharmacology 51 (1976) 15-22
202. Sayers, A., H. Bürki, W. Ruch, H. Asper: Animal models for tardive dyskinesia: effects of thioridazine. Pharmakopsychiat. 10 (1977) 291-295
203. Schechter, P.J., Y. Tranier, M.J. Jung: Antiseizure activity of δ-acetylenic δ-aminobutyric acid transaminase. J. Pharmacol. Exp. Ther. 201 (1977) 606-612
204. Schmidt, W.R., L. W. Jarcho: Persistent dyskinesia following phenothiazine therapy. Arch. Neurol. 14 (1966) 369-377
205. Sedman, G.: Clonazepam in treatment of tardive oral dyskinesia. Brit. Med. J. 1 (1976) 269
206. Seeler, W., F. Kulhanek: Späte extrapyramidal Hyperkinesen. Schwarzeck-Verlag München 1980
207. Sheppard, G., A. Mackay: Clonazepam in the treatment of tardive dyskinesia: a controlled study. III. World Congress of Biological Psychiatry Stockholm 1981
208. Sheppard, G., A. Mackay: Propranolol in the treatment of tardive dyskinesia. III. World Congress of Biological Psychiatry Stockholm 1981
209. De Silva, L., C.Y. Huang: Deanol in tardive dyskinesia. Brit. Med. J. 3 (1975) 466
210. Simpson, G.M., M.H. Branchey, J.H. Lee, A. Voitashevsky, B. Zoubok: Lithium in tardive dyskinesia. Pharmakopsychiat. 9 (1976) 76-80
211. Simpson, G.M., J.H. Lee, R.K. Shrivastava, M.H. Branchey: Baclofen in the treatment of tardive dyskinesia and schizophrenia. Psychopharmacol. Bull. 14 (1978) 16-18
212. Simpson, G.M., E. Varga: Clozapine - a new antipsychotic agent. Curr. Ther. Res. 16 (1974) 679-686
213. Simpson, G.M., A. Voitashevsky, M.A. Young, J.H. Lee: Deanol in the treatment of tardive dyskinesia. Psychopharmacology 52 (1977) 257-261
214. Simpson, G.M., J.H. Lee, R.K. Shrivastava: Clozapine in tardive dyskinesia. Psychopharmacology 56 (1978) 75-80
215. Singer, K., N.M. Cheng: Thiopropazate hydrochloride in persistent dyskinesia. Brit. Med. J. 4 (1971) 22-25
216. Singh, M.M.: Diazepam in the treatment of tardive dyskinesia. Int. Pharmacopsychiat. 11 (1976) 232-234
217. Smith, R.C., J. Davis: Behavioral supersensitivity to apomorphine and amphetamine after chronic high haloperidol treatment. Psychopharm. Comm. 1 (1975) 285-293
218. Smith, R.C., C.A. Tamminga, J. Haraszti, G.N. Pandey, J.M. J.M. Davis: Effects of dopamine agonists in tardive dyskinesia. Am. J. Psychiatry 134 (1977) 763-768
219. Sovner, R., A. Di Mascio: The effect of benztropine mesylate in the rabbit syndrome and tardive dyskinesia. Am. J. Psychiatry 134 (1977) 1301-1302
220. Sovner, R., A. Loadman: More on barbiturates and tardive dyskinesia. Am. J. Psychiatry 135 (1978) 382
221. Stille, G., H. Hippius: Kritische Stellungnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klini-schen Befunden mit Clozapin). Pharmakopsychiat. 4 (1971) 182-191
222. Tamminga, C.A., R.C. Smith, S.E. Ericksen, S. Chang, J.M. Davis: Cholinergic influences in tardive dyskinesia. Am. J. Psychiatry 134 (1977) 769-774
223. Tarsy, D., R.J. Baldessarini: The tardive dyskinesia syndrom. In: H.L. Klawans (ed.): Clinical Neuropharmacology Vol. 1. Raven Press 1973
224. Tarsy, D., N. Leopold, D. Sax: Physostigmine in choreiform movement disorder. Neurology 24 (1974) 28-33
225. Tarsy, D., J. Parkes, C. Marsden: Metoclopramide and pimozide in Parkinson's disease and levodopa induced dyskinesia. J. Neurol. Neurochir. Psychiat. 38 (1975) 331-335
226. Task Force Report on tardive dyskinesia of the American Psychiatric Association. Am. J. Psychiatry 137 (1980) 1163-1172
227. Tegeler, J.: Behandlung akut schizophrener Krankheitsbilder mit Benperidol. In: B. Müller-Oerlinghausen (ed.): Benperidol-Kolloquium Tropon. Das ärztliche Gespräch, Bd. 30, Köln 1980
228. Tegeler, J., E. Lehmann, M. Stockschldder: Zur Wirksamkeit der langfristigen ambulanten Behandlung Schizophrener mit Depot- und Langzeitneuroleptika. Nervenarzt 51 (1980) 654-661
229. Tell, G., P.J. Schechter, P. Koch-Weser, P. Cantiniaux, LP. Chabannes, P. Lambert: Gamma-vinyl-GABA, an irreversible, enzyme-activated GABA-transaminase inhibitor: Preliminary open study in tardive dyskinesia. III. World Congress of Biological Psychiatry, Stockholm 1981
230. Trillet, M., O. Joyeux, R. Masson: Tiapride et mouvements anormaux. Sem. Hop. 53 (1977) 21-27
231. Tolosa, E.S.: Modification of tardive dyskinesia and spasmodic torticollis by apomorphine. Arch. Neurol. 35 (1978) 459-462
232. Turek, I., A.A. Kurland, T.E. Hanlon, M. Bohm: Tardive dyskinesia … Its relation to neuroleptic and antiparkinson drugs. Brit. J. Psychiat. 121 (1972) 605-612
233. Turunen, S., K.A. Achte: The bucco-linguomasticatory syndrome as a side-effect of neuroleptic therapy. Psychiatr. Q. 41 (1967) 268-279
234. Uhrbrand, L., A. Faurbye: Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia 1 (1960) 408-418
235. Vale, S., M.A. Espejel: Amantadine for dyskinesia tarda. N. Engl. J. Med. 284 (1971) 673
236. Vasavan-Nair, N.P., R. Yassa, J. Ruis-Navarro, G. Schwartz: Baclofen in the treatment of tardive dyskinesia. Am. J. Psychiatry 135 (1978) 1562-1563
237. De Veaugh-Geiss, J., L. Manion: High-dose pyridoxine in tardive dyskinesia. J. Clin. Psychiat. 39 (1978) 573-575
238. Verhoeven, W.M.A., H.M. van Praag, P.A. Botter, A. Suncer, J.M. van Ree, D. de Wied: Des-tyr-6-endorphin in schizophrenia. Lancet (1978) 1046-1047
239. Villeneuve, A., Z. Böszörmenyi: Treatment of drug-induced dyskinesias. Lancet 1 (1970) 353-354
240. Viukari, M., M. Linnoila: Effect of fusaric acid on tardive dyskinesia and mental state in psychogeriatric patients. Acta Psychiat. Scand. 56 (1977) 57-61
241. Wertheimer, J.: Syndrome extra-pyramidaux permanents consecutifs a I'administration prolongee de neuroleptiques. Schweiz. Arch. Neurol. Neurochir. Psychiat. 95 (1965) 120-173
242. Widroe, H.J., S. Heisler: Treatment of tardive dyskinesia. Dis. Nerv. Syst. 37 (1976) 162-164
243. Wöller, L., W.J. Tegler: Späte extrapyramidal Hyperkinesen. Klinik - Prävalenz - Pathophysiologie. Fortschr. Neurol. Psychiat. 51 (1983) 131-157
244. Wright, J., G. Schrodt, R. Simpson, D. Moore, B. Davis: Propranolol treatment of tardive dyskinesia: Preliminary report of a placebo-controlled study. III. World Congress of biological Psychiatry, Stockholm 1981
245. Wurtman, R.J., N.J. Hirsch, J.H. Growdon: Lecithin consumption raises serum free-choline levels. Lancet 2 (1977) 68-69
246. Yagi, G., K. Ogita, N. Ohtsuka: Persistent dyskinesia after longterm treatment with neuroleptics in Japan. Keio. J. Med. 25 (1976) 27-35
247. Zahniser, N.R., T.M. Shih, U. Kopp, I. Hanin: Extent of 2- demethyl-aminoethanol (deanol) biotransformation to choline (Ch) and acetylcholine (Ach) in blood and brain: a gas chroma- tograph mass spectrometic (GC MS) analysis. Soc. Neuroc. Abstr. 3 (1977) 1054